Argatroban. Pharmacological properties and anaesthesiological aspects

被引：8
作者：
Kleinschmidt S. [1 ,3 ]
Stephan B. [2 ]
Pindur G. [2 ]
Bauer C. [1 ]
机构：
[1] Klinik für Anaesthesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum des Saarlandes, Homburg (Saar)
[2] Abteilung für Klinische Hämostaseologie und Transfusionsmedizin, Universitätsklinikum des Saarlandes, Homburg (Saar)
[3] Klinik für Anaesthesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum des Saarlandes
来源：
Der Anaesthesist | 2006年 / 55卷 / 4期
关键词：
Anticoagulation; Argatroban; Heparin-induced thrombocytopenia (HIT Type II); Thrombin inhibion;
D O I：
10.1007/s00101-005-0962-7
中图分类号：
学科分类号：
摘要：
Argatroban is a direct, selective and reversible active site thrombin inhibitor derived from L-arginine. It is a representative of a new class of antithrombotic drugs which offer inhibition of clot-bound as well as fluid-phase thrombin. Argatroban is characterised by favourable pharmacokinetics (β-elimination half-time approximately 40-50 min) undergoing hepatic metabolism and mainly biliary excretion. Renal impairment will not result in altered or delayed elimination. For many years, argatroban has been used in Japan and in the United States and is approved by the FDA for anticoagulation in patients with heparin-induced thrombocytopenia (HIT type II). The ease of monitoring with the activated partial thromboplastin time, lack of induction of antibodies and adequate safety in renal failure patients, make this drug a favourable mode therapy in comparison with other anticoagulants such as lepirudin or heparinoids. Since June 2005 argatroban has been approved in Germany for the treatment of patients with HIT type II. The main characteristics of the drug with special considerations for anaesthesiologists and intensive care physicians are presented in this review. © Springer Medizin Verlag 2006.
引用
收藏
页码：443 / 450
页数：7
相关论文
共 27 条
[1]  
Dager W.E., White R.H., Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD, Ann Pharmacother, 37, pp. 1232-1236, (2003)
[2]  
Rückenmarknahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation, Anaesthesiol Intensivmed, 44, pp. 218-230, (2003)
[3]  
Dyke P., Russo P., Mureebe L., Et al., Argatroban for anticoagulation during cardiopulmonary bypass in an infant, Pediatr Anesth, 15, pp. 328-333, (2005)
[4]  
Gasparovic H., Nathan N., Fitzgerald D., Et al., Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia, Ann Thorac Surg, 78, pp. 89-91, (2004)
[5]  
Greinacher A., Lubenow N., Hinz P., Ekkernkamp A., Heparininduzierte Thrombozytopenie, Dtsch Arztebl, 100, 34-35, (2003)
[6]  
Harenberg J., Jorg I., Tivadar F., Et al., Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban, J Thromb Thrombolysis, 19, pp. 65-69, (2005)
[7]  
Jang I., Lewis B.E., Matthai W., Et al., Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa Inhibition in patients undergoing percutaneous coronary intervention: An open-label, non-randomized pilot study, J Thromb Thrombolysis, 18, pp. 31-37, (2004)
[8]  
Kathiresan S., Shiomura J., Jang I.K., Argatroban, J Thromb Thrombolysis, 13, pp. 41-47, (2002)
[9]  
Kleinschmidt S., Seyfert U.T., Die Heparin-induzierte Thrombozytopenie. Bedeutung für Anästhesie und Intensivmedizin, Anaesthesist, 48, pp. 771-785, (1999)
[10]  
Lewis B.E., Hursting M., Argatroban in heparin-induced thrombocytopenia, Heparin-induced Thrombocytopenia, pp. 381-407, (2001)
123